4:33 PM
 | 
Jan 11, 2008
 |  BC Extra  |  Top Story

Cadence off after Acetavance miss

Cadence (NASDAQ:CADX) fell $8.63 (62%) to $5.36 on Friday after reporting that IV Acetavance missed the primary endpoint in one of two double-blind, U.S. Phase III trials. In Study 301 to treat post-operative pain following abdominal gynecological surgery in 331 patients, the...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >